With clinical trials facing multiple challenges, digital solutions could provide the answer. We identify the key trends to ...

A2 Biotherapeutics has secured $80m in funding to advance its pipeline of CAR-T cell therapies for solid tumour cancers.

Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising CLYM116.

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services.

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

The EC has approved the extension of Stallergenes Greer’s Palforzia for the treatment of peanut allergy in toddlers.

Aspect Biosystems has secured $115m in a Series B financing round to advance the development of bioprinted tissue therapeutics.

The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with hepatocellular carcinoma (HCC).

Financing was co-led by Forbion and General Atlantic, with participants including RA Capital Management, OrbiMed, and Lilly Asia Ventures.

The heart failure market is expected to grow at a 9.6% CAGR from $13.5bn in 2022 to $33.7bn in 2032 in the 7MM.